Does Blue Cross Blue Shield of Texas Cover Eliquis?

What Is Eliquis and Why Coverage Matters

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) manufactured by Bristol-Myers Squibb and Pfizer. It is FDA-approved for five indications: reducing stroke and systemic embolism risk in nonvalvular atrial fibrillation, treating deep vein thrombosis (DVT) and pulmonary embolism (PE), reducing recurrent DVT/PE risk after initial therapy, and prophylaxis of DVT after hip or knee replacement surgery. The FDA's full prescribing information is publicly available on the agency's accessdata portal. [1]

Because atrial fibrillation affects roughly 2.7 million Americans and is the most common cardiac arrhythmia managed in outpatient settings, Eliquis is one of the highest-volume brand-name prescriptions in the United States. [2] Cost without coverage can exceed $600 per month, making insurance formulary placement a life-or-death financial issue for many patients in Texas.

How Formulary Tiers Work at BCBS Texas

Blue Cross Blue Shield of Texas (BCBSTX) uses a tiered formulary system, typically with four to six tiers depending on the plan design:

• Tier 1: Preferred generics (lowest copay, usually $0, $15)
• Tier 2: Non-preferred generics or preferred brands
• Tier 3: Preferred brand-name drugs (moderate copay, commonly $40, $60)
• Tier 4: Non-preferred brand-name drugs (higher cost-sharing, often $75, $150+)
• Tier 5/Specialty: High-cost specialty drugs (coinsurance up to 30 to 40%)

Eliquis lands on Tier 3 or Tier 4 on most BCBSTX commercial plans as of 2025. Specialty tier placement is less common for Eliquis than for biologics, but it does occur on certain employer self-funded plans where the employer customizes the formulary independently.

Why Tier Placement Varies So Much

BCBSTX administers both fully insured group plans and self-funded employer plans (also called ASO plans). Self-funded employers set their own formularies, meaning two patients with "BCBS Texas" cards may face completely different tier placements and prior authorization rules for the exact same drug. If your card says "Administered by BCBS of Texas" rather than showing BCBSTX as the insurer, your employer is likely self-funded and has more control over what gets covered.

Does BCBS Texas Require Prior Authorization for Eliquis?

Prior authorization (PA) is required for Eliquis on most BCBSTX plan types. This is standard across major commercial insurers because apixaban is a high-cost brand with no generic equivalent as of early 2025. The PA process requires your prescriber to submit clinical documentation demonstrating medical necessity. [3]

What Clinical Criteria BCBS Texas Typically Requires

PA criteria for Eliquis at BCBSTX generally mirror national clinical guideline thresholds. Based on published insurer medical policies and standard UM criteria, expect the PA to ask for:

1. Confirmed diagnosis supported by ICD-10 code (e.g., I48.x for atrial fibrillation, I82.x for DVT, I26.x for PE).
2. CHA2DS2-VASc score of 2 or greater for atrial fibrillation patients, which aligns with the 2023 ACC/AHA atrial fibrillation guideline recommendation for anticoagulation initiation. [4]
3. Documented contraindication, intolerance, or failure of warfarin (or generic rivaroxaban on plans requiring step therapy). Warfarin is a Tier 1 generic; insurers often ask that it be tried first unless a specific contraindication is documented.
4. Prescriber attestation that apixaban is preferred over other available DOACs for this specific patient.

Step Therapy: The Warfarin-First Requirement

Step therapy means the insurer requires a patient to try and fail (or demonstrate contraindication to) a cheaper drug before the preferred brand is approved. On many BCBSTX plans, warfarin at Tier 1 is the required first step for anticoagulation. In practice, warfarin has a narrow therapeutic index, requires frequent INR monitoring, and interacts with dozens of common medications and foods. [5]

The 2019 Texas step therapy law (Texas Insurance Code Chapter 1369, Subchapter J) gives patients the right to request an exception to step therapy when a specific clinical condition makes the required first-step drug unsuitable. Your prescriber can cite labile INR history, drug-drug interactions, patient lifestyle factors, or fall risk to support the exception.

How to Check If Your Specific BCBS Texas Plan Covers Eliquis

Not every BCBSTX plan uses the same formulary. Here is the fastest way to verify your coverage before picking up a prescription.

Step 1: Locate Your Formulary Online

Log into your BCBSTX member portal at bcbstx.com. Under "Benefits and Coverage," select "Drug List" or "Formulary." Enter the drug name "apixaban" or brand name "Eliquis." The search result will show the tier, any required PA, and whether quantity limits apply.

Step 2: Call the Member Services Number on Your Card

The number on the back of your insurance card routes to a pharmacist or benefits specialist who can confirm real-time coverage. Ask specifically: (a) what tier is Eliquis on my plan, (b) is prior authorization required, (c) is there step therapy, and (d) what is my estimated copay after deductible.

Step 3: Ask Your Pharmacist to Run a Test Claim

A pharmacist can run your insurance information against a test claim for Eliquis before you commit to the prescription. This shows the exact price your plan would charge today, including any PA holds.

Eliquis Coverage Under BCBS Texas Medicare Advantage Plans

BCBSTX offers multiple Medicare Advantage (MA) plans in Texas, including HMO and PPO options. Eliquis coverage under Medicare Advantage is governed by CMS Part D rules, which require formulary coverage for anticoagulants used in atrial fibrillation. [6]

Tier Placement and Cost-Sharing Under Medicare Advantage

Under most BCBSTX Medicare Advantage Part D formularies, Eliquis sits at Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Copays at Tier 3 on a typical MA-PD plan run $40, $60 per 30-day fill, but these numbers shift significantly once a beneficiary enters the deductible phase or the coverage gap (historically called the "donut hole"). Starting in 2025, the Inflation Reduction Act capped Medicare Part D out-of-pocket drug costs at $2,000 annually, which substantially changes the calculus for high-cost anticoagulants. [7]

The Copay Card Prohibition Under Medicare

Bristol-Myers Squibb and Pfizer offer a copay assistance card that can bring Eliquis cost to as low as $10 per 30-day fill for commercially insured patients. However, federal anti-kickback statute regulations prohibit the use of manufacturer copay assistance cards for any patient enrolled in a federal program, including Medicare Advantage, Medicare Part D, Medicaid, CHIP, or TRICARE. This is not a loophole-able rule. Medicare beneficiaries who need cost relief should ask about the Patient Assistance Program (PAP) offered by Bristol-Myers Squibb, which provides free drug to income-qualified patients, or ask their prescriber about the generic anticoagulant alternatives discussed below.

What Eliquis Costs Without or Before Coverage Kicks In

The cash price for Eliquis 5 mg (the most common dose for atrial fibrillation), for a 60-tablet supply (30-day supply at twice daily dosing), runs approximately $550, $620 at major Texas retail pharmacies as of early 2025. The 2.5 mg tablet, used for DVT prophylaxis and in dose-reduced AF patients meeting specific criteria, runs slightly lower at $450, $500 for 60 tablets.

GoodRx, Blink Health, and pharmacy-specific discount programs can bring this down to $450, $500 in some cases, but these are not combinable with insurance and require you to waive your insurance claim.

The Bristol-Myers Squibb Copay Assistance Program

Commercially insured patients (not on Medicare or Medicaid) can access the BMS/Pfizer Eliquis copay card through the program at eliquis.com. The program caps your monthly copay at $10 for up to 24 months, with a maximum annual benefit of $6,400. Eligibility requires:

• Active commercial insurance (BCBSTX commercial plans qualify)
• Not enrolled in any federal or state health insurance program
• Residing in the United States

Enrollment takes approximately five minutes online. The card is activated immediately and can be presented at the pharmacy on the same day.

Covered Alternatives to Eliquis on BCBS Texas Formularies

If prior authorization is denied or cost-sharing remains unaffordable, three other anticoagulant options may be covered at a lower tier on your BCBSTX plan.

Warfarin (Generic)

Warfarin is the original vitamin K antagonist oral anticoagulant. It is universally on Tier 1 of virtually every formulary, often at $0, $5 per fill. Its downsides: narrow therapeutic index, weekly to monthly INR blood testing, dozens of food and drug interactions, and significant dosing complexity. For well-controlled patients with stable INR and no drug-food conflicts, warfarin remains a clinically reasonable option.

Rivaroxaban (Xarelto, and Generic Rivaroxaban)

A generic version of rivaroxaban (Xarelto) became available in the United States in 2024 after Bayer's patent exclusivity ended. Generic rivaroxaban costs approximately $30, $60 per month and is likely to land on Tier 1 or Tier 2 on updated BCBSTX formularies. Rivaroxaban is dosed once daily for AF indications, which some patients find more convenient. The ROCKET-AF trial (N=14,264) showed rivaroxaban non-inferior to warfarin for stroke prevention in AF, with a similar bleeding profile. [8]

Dabigatran (Pradaxa)

Dabigatran (Pradaxa) is another factor IIa inhibitor DOAC. Generic dabigatran is not yet available in the US as of early 2025. It typically lands on Tier 3 or Tier 4 depending on the plan. The RE-LY trial (N=18,113) showed dabigatran 150 mg twice daily reduced stroke and systemic embolism by 34% compared to warfarin (relative risk 0.66, 95% CI 0.53 to 0.82, P<0.001). [9]

Comparing DOACs Clinically

The 2023 ACC/AHA/ACCP/HRS Atrial Fibrillation Guideline states: "For patients with AF and elevated stroke risk, DOACs are preferred over vitamin K antagonists in patients who can take them, given their more predictable pharmacokinetics and lower risk of intracranial hemorrhage." [4] This wording gives your prescriber strong guideline support when writing a PA exception letter arguing against mandatory warfarin step therapy.

The HealthRX clinical team has developed a one-page PA exception letter framework for BCBS Texas Eliquis denials that physicians can use during the prior authorization process. The framework organizes the required clinical documentation into four sections: diagnosis confirmation, CHA2DS2-VASc scoring, step-therapy exception criteria, and prescriber attestation. Ask your HealthRX care team for the current version.

How to Appeal a BCBS Texas Eliquis Denial

If BCBSTX denies your Eliquis prior authorization, you have multiple formal appeal pathways. The appeals process is governed by Texas Department of Insurance rules and federal ACA regulations for marketplace plans. [10]

Internal Appeal (Level 1)

Submit a written internal appeal within 180 days of the denial notice. Include:

• A letter of medical necessity from your prescribing physician citing the specific clinical indication, CHA2DS2-VASc score, INR history if applicable, and any contraindications to first-step drugs.
• Office visit notes or cardiology records documenting the diagnosis.
• A copy of the relevant ACC/AHA guideline pages supporting DOAC use.

BCBSTX is required to respond to standard appeals within 30 days and to urgent (expedited) appeals within 72 hours under Texas Insurance Code Section 1271.

External Independent Review (Level 2)

If the internal appeal fails, you can request an external independent review through the Texas Department of Insurance. An independent review organization (IRO) reviews the clinical documentation without involvement from BCBSTX. IRO decisions in Texas are binding on the insurer for coverage decisions. Data from the Texas Department of Insurance show that external reviewers overturn insurer denials in approximately 40 to 50% of cases when complete clinical documentation is submitted. [11]

Expedited Appeal for Urgent Cases

If stopping Eliquis creates imminent health risk (e.g., high-stroke-risk AF patient), request an expedited appeal. The insurer must respond within 72 hours. Document the urgency explicitly in writing.

BCBS Texas ACA Marketplace Plans and Eliquis

Patients who purchase coverage through HealthCare.gov in Texas and select a BCBSTX plan operate under ACA formulary rules. ACA plans must cover at least one drug in every therapeutic class. Eliquis is typically covered, but tier placement and PA requirements still apply.

The ACA Exception Request Process

ACA marketplace plans must have a formulary exception process. If Eliquis is not on your plan's formulary, or is on a tier that makes it unaffordable, you can request an exception. A physician statement that no alternative covered drug is clinically appropriate for your specific case satisfies the exception standard under 45 CFR 156.122.

For marketplace plan members, the low-income subsidy (cost-sharing reductions, or CSRs) can dramatically lower both premiums and drug copays on Silver-tier plans. A Silver plan with CSRs may have a $0 drug deductible and significantly reduced brand-name copays compared to the standard Silver benefit design.

Practical Steps: Getting Eliquis Covered at BCBS Texas

To summarize the action pathway in clinical order:

Before the Prescription Is Written

Ask your prescriber to check the BCBSTX formulary for your specific plan before sending the prescription. A PA-required drug sent directly to the pharmacy without a PA on file creates delays and confusion. Have your prescriber's office submit the PA electronically at the same time as the prescription.

If the PA Is Approved

Enroll in the BMS/Pfizer copay assistance card immediately if you are commercially insured (not Medicare). The card reduces your copay to as low as $10/month. Many patients miss this step and overpay for months.

If the PA Is Pending or Denied

Request a bridge supply. Some pharmacies and your prescriber may be able to provide a 7 to 14 day starter sample while the PA is processed. Bristol-Myers Squibb also offers a free trial supply through its patient support program for eligible patients.

Ask your prescriber's office to contact the BCBSTX pharmacy prior authorization line directly. Many PA denials at the initial stage are due to incomplete submission, not clinical ineligibility. Resubmission with complete documentation resolves the issue faster than formal appeal in many cases.

Key Statistics on Eliquis and Anticoagulation Outcomes

Clinical evidence should drive the coverage conversation between you and your insurer. Here are three specific trial results your prescriber can reference in a PA letter:

1. The ARISTOTLE trial (N=18,201) showed apixaban reduced stroke or systemic embolism by 21% compared to warfarin (hazard ratio 0.79, 95% CI 0.66 to 0.95, P<0.01), with a 31% reduction in major bleeding (HR 0.69, P<0.001). [12]

2. The AMPLIFY trial (N=5,395) showed apixaban was non-inferior to enoxaparin/warfarin for treatment of acute VTE and was associated with 69% less major bleeding (relative risk 0.31, 95% CI 0.17 to 0.55, P<0.001). [13]

3. A 2021 real-world comparative effectiveness study published in JAMA Network Open (N=581,451 AF patients) found apixaban users had significantly lower rates of ischemic stroke (HR 0.82) and intracranial hemorrhage (HR 0.60) compared to warfarin users in a US commercial insurance population. [14]

These numbers give clinical justification for why switching a stable Eliquis patient to warfarin purely for cost reasons may increase adverse event risk, and that argument belongs in every PA exception letter.